AT&T Stock Quote SOBA - Stock Price, News, Charts, Message Board, Trades

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
Germany
TG
AT&T Inc (SOBA) Quote

AT&T Inc (SOBA)

22.145

-0.11

( -0.49% )

Updated: 07:46:47

Realtime Data

Professional-Grade Tools, for Individual Investors.

Current Price

22.145

Bid

22.105

Ask

22.125

Volume

28,601

22.005 Day's Range 22.235

14.62 52 Week Range 22.375

Market Cap

Previous Close

22.255

Open

22.20

Last Trade

Last Trade Time

07:40:24

Financial Volume

-

VWAP

-

Average Volume (3m)

56,029

Shares Outstanding

7,175,289,157

Dividend Yield

5.25%

PE Ratio

11.72

Earnings Per Share (EPS)

1.98

Revenue

122.43B

Net Profit

14.19B

Sector

Phone Comm Ex Radiotelephone

Industry

Phone Comm Ex Radiotelephone

Website

www.att.com

Headquarters

Wilmington, Delaware, USA

Founded

-

AT&T Inc is listed in the Phone Comm Ex Radiotelephone sector of the Tradegate (DE) with ticker SOBA. The last closing price for AT&T was 22.26 €. Over the last year, AT&T shares have traded in a share price range of 14.62 € to 22.375 €.

AT&T currently has 7,175,289,157 shares outstanding. The market capitalization of AT&T is 159.69 € billion. AT&T has a price to earnings ratio (PE ratio) of 11.72.

No news to show yet.

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.665	3.09590316574	21.48	22.375	21.309999	50800	21.83247803	DE
4	1.92	9.49320148331	20.225	22.375	20.035	52482	21.06466936	DE
12	4.217	23.5218652387	17.928	22.375	17.794	56029	20.05450311	DE
26	6.051	37.5978625575	16.094	22.375	15.772	44334	18.88552941	DE
52	7.38	49.9830680664	14.765	22.375	14.62	43514	17.33547697	DE
156	0.245	1.11872146119	21.9	24.2	12	34188	17.38594917	DE
260	-12.49	-36.0617872095	34.635	35.82	12	29863	19.92119578	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
2BC0Panther Minerals Inc	0.05 € (69.49%)	461.56k
AXIAtos SE	0.268 € (67.50%)	1.27M
BDDConico Ltd	0.0008 € (33.33%)	630k
A4YACCENTRO Real Estate AG	0.348 € (28.89%)	3.96k
GC3Novonix Limited	0.5795 € (25.05%)	23.82k
CNWCodon AG	0.007 € (-36.36%)	1.72k
AVHAkoustis Technologies Inc	0.064 € (-35.03%)	164.05k
27N0Cannovum Cannabis AG	0.29 € (-31.92%)	54.27k
5ZOLiMetal Corp	0.0342 € (-22.97%)	400
R2FAGreenwing Resources Ltd	0.0205 € (-22.64%)	5.7k
D7GNel ASA	0.2652 € (3.15%)	5.87M
FMKEcograf Limited	0.0524 € (6.94%)	1.49M
9CHGalan Lithium Limited	0.089 € (-1.98%)	1.28M
AXIAtos SE	0.268 € (67.50%)	1.27M
CBKCommerzbank AG	14.42 € (-5.84%)	841.59k

baltimorebullet

baltimorebullet 4 minutes ago

How about a the acceptance of a peer-reviewed manuscript titled, “Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial,”

NEW YORK – November 25, 2024
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasda

Checkmate 36

Checkmate 36 4 minutes ago

Marty,
Take a deep breath, think for a second, and don’t be so myopic.

If you are searching for hope for this company to succeed…..which one can assume that’s what your doing as you state, your a long, you need to take your “readers” off, take the blinders off, and really let

glenn1919

glenn1919 4 minutes ago

RGTI.....NVTS......https://stockcharts.com/h-sc/ui?s=NVTS&p=W&b=5&g=0&id=p84354014936

kaisdaboss88

kaisdaboss88 4 minutes ago

$DPUI tiny os history of making huge moves with a 600million OS this will run wild when volume comes in loading tickets here.

Guzzi62

Guzzi62 4 minutes ago

So all the posters thinking a peer review would never happen are likely keeping a low profile today.

I don't see any name mentioned regarding the journal, expect: medical journal with focus on Alzheimer’s disease.

Further in the press release: “We are on track for regu

tw0122

tw0122 4 minutes ago

.58 flipping half from .47

kaisdaboss88

kaisdaboss88 5 minutes ago

$VNTH another low floater dilution free shell insiders own many shares solid loading opportunities

VoyagerRealm96

VoyagerRealm96 5 minutes ago

No.more shell risk on OTC 😍😍😍😍😍😍

glenn1919

glenn1919 6 minutes ago

QMCO....WLDS....MULN......................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936

kaisdaboss88

kaisdaboss88 6 minutes ago

$PRDL nice dilution free shell insiders own 700mill shares keep on your radar.

Hoskuld

Hoskuld 6 minutes ago

Simufilam did not meet endpoints: https://finance.yahoo.com/news/cassava-sciences-topline-phase-3-123000846.html

tw0122

tw0122 7 minutes ago

.53 style="caret-color: rgb(0, 0, 0); color: rgba(0, 0, 0, 1); font-family: -apple-system; font-size: 15px"“We now have evidence that the dramatic reduction of cognitive decline that was sustained over 6 months in patients treated with CT1812 who had lower plasma p-tau217 levels also was associated

BornAgain

BornAgain 7 minutes ago

$BWMG is the only profitable company that sells for .006!!!

Could this be a zip code changer!!! Do your own DD.

https://www.otcmarkets.com/filing/html?id=17989053&guid=F5Y-kqhAVXGaJth

cfoofme

cfoofme 8 minutes ago

The same IMMINENT news you posted 2-3 years ago. Please update us re which of those will occur between now and end of 2024. Thanks.

PonkenPlonken

PonkenPlonken 9 minutes ago

SAVA will be toast on open. Their cognitive improvement in Alzheimers is beaten by daily stretching and taking a walk in patients.
Atleast they canceled their other ph3 trial.... They have raised false hopes in too many patients already.
Question is will they face legal consequences fo

tw0122

tw0122 9 minutes ago

.47 . - Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology -

WilliamMunny

WilliamMunny 10 minutes ago

Goodbye Cassava

linkvest

linkvest 10 minutes ago

Doubt that is going to happen.... Hitting the 7s already this morning LOLOL>..

Risk vs Reward

Risk vs Reward 10 minutes ago

Magnum7419

Magnum7419 11 minutes ago

This is worth a repeat imho!!!!!!!!!!!!

Read earlier posts on RSS before you comment . There will be no RSS for 18-24 months. Only when we are ready and ""approved"" to uplist. There is no advantage for us over investors. When and if it happens it affects us as well.

Hoskuld

Hoskuld 12 minutes ago

tredenwater, OL trials are problematic in AD - we have seen that several times. I love the idea of a limited look and adjustment but not OL. I also really like Anavex's approach to trials - except for the size and number. FWIW, Anavex itself admits it screwed up - it was trying to do the bare min

Truthsocial

Truthsocial 12 minutes ago

https://www.prageru.com/video/dr-marty-makary-on-eye-opening-discoveries-in-health-and-medicine

New FDA COMMISSIONER SOON ENOUGH from JOHNS HOPKINS
help is arriving to clean out the skat
And the garbage finally

RDGL coming soon enough
MAYO CLINI

Shonnieville

Shonnieville 12 minutes ago

She'll risk removed on the otc profile!

Let's go!

Doc328

Doc328 12 minutes ago

“Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial,” in a medical journal with focus on Alzheimer’s disease.

WTF, top tier I'm sure

tradernewstip

tradernewstip 13 minutes ago

$ILLR On alert!! Former Head of Product at TikTok Sean Kim joins Triller Group https://finance.yahoo.com/news/former-head-product-tiktok-sean-133000625.html

Delayed Upgrade Clock